Stockreport

Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting

Trevena, Inc.  (TRVN) 
Last trevena, inc. earnings: 3/12 07:01 am Check Earnings Report
US:NASDAQ Investor Relations: investors.trevena.com/investor-relations
PDF Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena [Read more]